biosimilar drugs

FDA okays biosimilar for several cancersWhile FDA has approved a handful of biosimilar drugs, the agency just approved the first biosimilar that treats a variety of types of cancer.
Law Reauthorizes FDA Fees and Increases Access to Generics/BiosimilarsSenate passes FDARA overwhelmingly, ahead of September deadline.
Biosimilars Market Taking Off in the United StatesAfter many years of speculation, a number of biosimilar drugs are hitting the U.S. market.
Biosimilars Have Entered the Market, But Are They Safe?Biosimilars are starting to come on the market, but some have questions about their safety.
Retailers and PBMs Laud Generic/Biosimilar Savings
Retailers and PBMs Laud Generic/Biosimilar SavingsSavings from generic and biosimilar drugs are making PBMs and pharmacies, as well as patients, happy.
Pharmacists: Key Players as Biosimilars Enter the MarketPharmacists will have a central role in educating about biosimilar drugs.
Biosimilars Come  to Community Pharmacy
Biosimilars Come to Community PharmacyBiosimilars are now being dispensed from community pharmacies.
Biosimilar of Remicade Launched
Biosimilar of Remicade LaunchedRenflexis has wholesale cost 35% below Remicade.
Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
FDA clears second Remicade biosimilarIn what is expected to produce hefty saving for rheumatoid arthritis patients and the healthcare system, FDA approved the second biosimilar to Remicade (Johnson & Johnson).